Katherine Gehlhausen
Internal Medicine · Indianapolis, INNPI 1205281441
Payments from drug & device makers
Across 109 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$386
- Novo Nordisk$288
- Pfizer$112
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$111
- Abbott$103
- Otsuka America Pharmaceutical, Inc.$56
- plus $667 from 22 others
What the payments were for
- Food & beverage$1,723100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $386 |
| Novo Nordisk | 19 | $288 |
| Pfizer | 8 | $112 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $111 |
| Abbott | 6 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $56 |
| Boehringer Ingelheim | 3 | $53 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Exact Sciences | 3 | $50 |
| Mylan Specialty L.p. | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| AstraZeneca | 3 | $41 |
| AbbVie | 2 | $41 |
| GSK | 2 | $34 |
| Amgen | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Merck | 2 | $29 |
| Biogen | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Novartis | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
How this compares
$1,723 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 68 | $75,571 |
| EliquisApixaban | 46 | $43,166 |
| RybelsusSemaglutide | 27 | $34,247 |
| OzempicSemaglutide | 30 | $31,940 |
| MounjaroTirzepatide | 20 | $28,106 |
| XareltoRivaroxaban | 11 | $17,826 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,375 |
| FarxigaDapagliflozin Propanediol | 19 | $13,416 |
| EntrestoSacubitril/Valsartan | 13 | $9,238 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,460 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $5,031 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $3,403 |
| Atorvastatin Calcium | 546 | $3,344 |
| SynthroidLevothyroxine Sodium | 61 | $3,256 |
| Levothyroxine Sodium | 355 | $3,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $53 | $75,57168 claims |
| Novo NordiskRybelsus, Ozempic | $288 | $66,18757 claims |
| PfizerEliquis, Paxlovid | $112 | $44,59566 claims |
| Lilly USA, LLCMounjaro | $386 | $28,10620 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $34 | $21,83530 claims |
| Johnson & JohnsonXarelto | $23 | $17,82611 claims |
| AstraZenecaFarxiga | $41 | $13,41619 claims |
| NovartisEntresto | $27 | $9,23813 claims |
| AbbVieSynthroid | $41 | $3,25661 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $3,083355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Indianapolis
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- Georgiann LinnemeierIndianapolis$692K
- Allon FriedmanIndianapolis$524K
- Eromonsele IdahosaIndianapolis$471K
- Misty ShieldsIndianapolis$411K
- Pei LuIndianapolis$298K
- Paul DexterIndianapolis$161K
- Jon DukeIndianapolis$138K
- Napoleon MamintaIndianapolis$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.